Slide 1: Investor Update
Investor Update January 2025 Bringing hope to people living with Alzheimer's Disease
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation has been prepared by Alpha Cognition Inc. (“ACI” or the “Company”). This presentation includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this present
Slide 3: ZUNVEYL Has Received FDA Approval to Treat Alzheimer's Disease
ALPHA COGNITION’S ORAL THERAPY ZUNVEYL HAS RECEIVED FDA APPROVAL TO TREAT ALZHEIMER'S DISEASE The Second Oral Therapy Approved This Decade, ZUNVEYL’s Dual MOA Was Designed to Minimize Drug Absorption in the Gastrointestinal (GI) Tract, Potentially Addressing Certain Tolerability Issues with Leading
Slide 4: Commercial & R&D Biopharmaceutical Company Focused on Neurodegenerative Diseases
COMMERCIAL & R&D BIOPHARMACEUTICAL COMPANY FOCUSED ON NEURODEGENERATIVE DISEASES ZUNVEYL® – Differentiated Treatment Potential for ALZHEIMER’S DISEASE • Large US 11M annual prescription (Rx) market characterized by high drug dissatisfaction and discontinuation1 • Oral therapy uniquely designed to re
Slide 5: Alpha Cognition Clinical Pipeline
ALPHA COGNITION CLINICAL PIPELINE Preclinical Phase 1 Phase 2 Phase 3 /Pivotal Approved 2025 Alzheimer’s Dementia Advancement Oral: Mild-to-Moderate Alzheimer’s Disease (AD) Complete Sublingual Formulation: formulation and Mild-to-Moderate Alzheimer’s Disease (AD) pharmacokinetic studies Moderate-to
Slide 6: Cathy Parker, MSN, GNP-BC
Cathy Parker, MSN, GNP-BC VP Value Based Care, Eventus WholeHealth COPYRIGHT 2021 ALPHA COGNITION, INC. 6
Slide 7: Alzheimer's Disease Represents Key Focus of Treatment In Nursing Homes
Alzheimer’s Disease Represents Key Focus of Treatment In Nursing Homes Quality Measures and Star Ratings Consequences of Untreated Alzheimer's Disease • Cognitive decline progresses rapidly, resulting in • Focus areas for nursing homes to attract residents and a greater risk of developing severe dem
Slide 8: Current Approaches to Alzheimer's Disease Management
Current Approaches to Alzheimer’s Disease Management Current approaches to Alzheimer's disease management Effective AD Adapt to new Personalize the As patients experience management involves treatment and issues treatment plan new symptoms or experience adverse events care team approach regarding di
Slide 9: Current Treatment Options
Current Treatment Options • Recommended first-line acetylcholinesterase inhibitors (AChEIs) have treatment-limiting side effects1 • 55% patients discontinue their AD medication due to side effects1 Medication Positive attributes Negative attributes Familiarity, Once daily dosing, Generic, Mild to Se
Slide 10: Where ZUNVEYL May Help Medical Professionals In Long Term Care
Where ZUNVEYL May Help Medical Professionals In Long Term Care Benefits of appropriate Alzheimer's disease treatment may include: For residents: Reduce cognitive decline1 Reduce mortality risk1,2 Minimize: risk of dehydration/UTIs, skin breakdown weight loss falls Reduce impact of gast
Slide 11: Hany Mohamed, Pharm.D., R.Ph., BCGP, BCMTMS
Hany Mohamed, Pharm.D., R.Ph., BCGP, BCMTMS Director of Clinical Services at LI Script COPYRIGHT 2021 ALPHA COGNITION, INC. 11
Slide 12: LTC Pharmacy Perspective
LTC Pharmacy Perspective Operational Pharmacy Consultant Pharmacist Monthly Individual Resident Chart & Medication Drug Acquisition and Dispensing Reviews Medication Therapy Management & Related Drug Utilization Reviews Medication Recommendations to Providers Resolving Third Party Payor Insurance Co
Slide 13: Flow of Patient/Resident
Flow of Patient/Resident Operational pharmacy will “see” Consultant pharmacist reviews the resident first resident chart within 30 days Med orders screened for Missing drug-diagnosis / duplicates, drug interactions, diagnosis-drug, lab results, drugs doses, coverage, etc. to treat adverse reactions
Slide 14: How does ALZ diagnosis and treatment take place
How does ALZ diagnosis and treatment take place Pharmacists largely leave the diagnosing to the physicians and NP’s Keys for Treatment Safety – minimize adverse events Efficacy – measurable results Ease of use – • Easy oral administration (size of “pill”) • 1-2 times a day with or without food COPYR
Slide 15: Issues with current therapies
Issues with current therapies Sleep disturbance/insomnia1,2 – Some residents with dementia are simply not treated additive upon already altered sleep • More rapid cognitive decline in untreated patients7 patterns • Risk of polypharmacy to treat behaviors • Risk of the need to use restraints GI side
Slide 16: How does ALZ treatment tie to long stay quality measures
How does ALZ (medication) treatment tie to long stay quality measures (QM’s) About 1/3 of long stay QM’s are directly or indirectly related to medication use QM’s directly or indirectly tied to (a) medication use or (b) lack of appropriate medication use A cascade of potential negative outcomes is p
Slide 17: ZUNVEYL may address both treated and untreated mild to moderate AD residents
ZUNVEYL may address both treated and untreated mild to moderate AD residents Residents who are untreated Who may have experienced adverse events from previous therapies Due to issues with transitions of care Experiencing polypharmacy due to AD associated behaviors Have discontinued AD treatments in
Slide 18: Commercial Strategy
Commercial Strategy COPYRIGHT 2021 ALPHA COGNITION, INC. 18
Slide 19: ZUNVEYL's differentiated profile will make a meaningful difference
ZUNVEYL’s differentiated profile will make a meaningful difference in the lives of those affected by Alzheimer’s disease Designed to minimize absorption in the stomach to avoid stimulation of the GI nervous system Purposefully Designed GALANTAMINE RIVASTIGMINE DONEPEZIL Prodrug Technology Protects f
Slide 20: AChEI market large but dissatisfied, creating opportunity in long term care
AChEI’s market large but dissatisfied creating opportunity for improved treatment option, specifically in long term care (LTC) Large, but dissatisfied market creates significant market opportunity Prescriptions by Specialty1 11M AChEI RX’s dispensed High discontinuation rates each year1 due to side-
Slide 21: Alzheimer's dementia affects 70% of LTC residents & 88% of LTC doctors likely to prescribe
Alzheimer’s dementia affects 70% long term care (LTC) residents & 88% LTC doctors likely to prescribe Large, Underserved LTC Market 6.7M In Nursing Homes, Alzheimer’s Dementia: 5.4M 1.2M Affects Is the leading Is the leading 70% reason for cause of death1 residents1 placement1 Significant Dissatisfa
Slide 22: ZUNVEYL Alzheimer's dementia opportunity in LTC
ZUNVEYL Alzheimer's dementia opportunity in LTC Limited payor barriers with 33 Person Commercial Team 70% of residents Covers >80% of the LTC Segment 40K-99K Target largest geographies with highest concentration of LTC AD lives Experienced, account- based sales team with Develop strategic and demons
Slide 23: Commercial team build and market access progress underway
Commercial team build and market access progress underway WAC pricing $749 per month Commercial Leaders and Team Pricing in-line with analog and market Onboarded research 350 years commercial experience Top 5 plans represent more than three- 150 years in long term care fourths of Part D Enrollees1 1
Slide 24: ZUNVEYL Alzheimer's dementia opportunity
ZUNVEYL Alzheimer's dementia opportunity Large but Dissatisfied Market Additional Development Programs LTC represents largest AD ZUNVEYL sublingual tablet prescription volume formulation and pharmacokinetic work >50% discontinue treatment at 12 months ALPHA-1062 pre-clinical final data for DOD bomb